- The FDA has signed off and removed the clinical hold for a cryopreserved formulation of Gamida Cell Ltd's GMDA GDA-201, an off-the-shelf cell therapy candidate for follicular and diffuse large B cell lymphomas.
- Gamida Cell expects to initiate a Phase 1/2 clinical study in patients with follicular and diffuse large B-cell lymphomas in 2022.
- In an investigator-sponsored Phase 1/2 study in relapsed or refractory lymphoma, treatment with the fresh formulation of GDA-201 with rituximab demonstrated significant clinical activity.
- Also Read: Gamida Cell Shares Surge On Rolling Omidubicel Marketing Application In US.
- Of the 19 patients with non-Hodgkin lymphoma (NHL), 13 complete responses and one partial response were observed, with an overall response rate of 74% and a complete response rate of 68%.
- At the December 2021 Annual Meeting of the American Society of Hematology, two-year follow-up data were reported on outcomes and cytokine biomarkers associated with survival.
- The data demonstrated a median duration of response of 16 months and overall survival at two years of 78%.
- Price Action: GMDA shares are up 10.6% at $3.12 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in